Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 55 of 65 · 3097 articles
This study identifies an immune pathway (IDO–AhR) that a parasite-derived antigen appears to activate to reduce experimental colitis in mice. That pathway is relevant because it helps explain how immune regulation might...
Measuring both how severe inflammation is and how much of the colon is affected could give a fuller picture of disease burden than current focal endoscopic scores. For patients with UC, that may affect risk assessment...
The work models how Mycobacterium avium can provoke epithelial inflammation similar to Crohn's disease, pointing to possible molecular links between infection and CD-like pathology that could guide future research.
Researchers are exploring methods to make probiotic therapies more stable through the digestive tract and to deliver anti-inflammatory molecules directly where intestinal inflammation produces high reactive oxygen...
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...
This study shows a mechanism by which IL-10 protects gut epithelial mitochondria and barrier function during exposure to an IBD-associated E. coli strain, which could be relevant to understanding pathways that maintain...
Researchers are exploring microbiome-derived molecules as targeted, locally acting therapies for ulcerative colitis that might avoid systemic immunosuppression. EB1010 showed anti-inflammatory activity and...
The study suggests a new host-directed mechanism that helps a common beneficial gut bacterium (Faecalibacterium prausnitzii) colonize and protect the gut lining, and identifies heparan sulfate as a potential way to...
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
The review shows increasing research linking ferroptosis to autoimmune diseases including IBD and ulcerative colitis, which may guide future biomarker and therapy research relevant to people with Crohn's disease or other...
This preclinical study suggests an herbal capsule formulation reduced colitis severity and shifted markers of oxidative stress, inflammation, and ferroptosis in mice — signaling possible biological pathways for future...
A blood biomarker that rises with active ulcerative colitis could help patients and clinicians monitor disease activity without relying solely on invasive tests. This study reports that serum type 23 collagen ectodomain...
This large, population-based study suggests people with Crohn's disease have modestly higher overall mortality than matched controls and higher deaths from specific causes (colorectal cancer, renal disease, non-Hodgkin...
The study suggests that while Crohn's disease produces a shared dysbiotic signature at diagnosis, the specific microbes enriched differ by age — notably oral-associated taxa in children — which could affect research into...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gut and liver.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Researchers used machine learning to prioritize microbiome-related regulatory targets in Crohn's disease, which may guide future lab and clinical research into microbial pathways (like butyrate-related metabolism) that...
If validated, the study points to a specific neutrophil subset that may drive inflammation and barrier damage in IBD, and to CXCR4 as a possible therapeutic target. That could open new biology-based treatment approaches...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
The study links a common commensal fungus, Candida albicans, to a focused Th17 immune response that can turn harmful in Crohn’s disease, identifying a specific cell population that could be targeted more precisely than...
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Crohn's disease, and Research and clinical...
If validated, a blood biomarker (LRG) could help predict which people with Crohn’s disease are more likely to achieve remission and which biologic might be sustained over a year, informing treatment planning and...
People with UC have higher rates of low bone density, which raises fracture risk. This study links altered hormones (leptin, ghrelin, IGF‑1) and inflammation to lower BMD in UC, suggesting metabolic pathways that could...
The study targets oxidative stress and the TXNIP/NLRP3 inflammasome axis, both implicated in IBD inflammation and barrier damage. If translatable, nanozyme-assisted probiotic therapy could offer a novel, targeted way to...
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
This trial tests whether raising the upadacitinib dose to 45 mg can recapture clinical response in people with ulcerative colitis who lost response on the 30 mg maintenance dose. If effective and safe, the approach could...
People with Crohn's disease commonly experience menstrual cramps, but there is little trial evidence comparing common OTC pain medicines in this group. This pilot trial aims to test whether a larger randomized study is...
This trial tests palmitoylethanolamide (PEA), a commercially available supplement with anti-inflammatory actions, as an add-on treatment for mild-to-moderate ulcerative colitis.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...
The gut microbiome differed more in pediatric Crohn’s disease and acute pancreatitis than in IBS or healthy kids, suggesting microbial changes are stronger in organic inflammatory disease and could be targets for future...
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
The study identifies a food-processing method (black tea processing) that increased flavonoids and improved outcomes in a mouse model of colitis, suggesting that specific dietary preparations might influence gut...
Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...
New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.
The paper suggests a mechanistic link between gut microbial gas production and mitochondrial function, which could be relevant for understanding metabolic stress and inflammation in IBD.
Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...
Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.
Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...
The study identifies a potential biologic approach (macrophage-derived exosomes) that improved epithelial repair and barrier function in a mouse colitis model, which could inform future therapeutic research for IBD.
